share_log
Reuters ·  Dec 20 20:10
Innovent Receives Approval of Dovbleron® (Taletrectinib Adipate Capsule, Ros1 Inhibitor) by China's National Medical Products Administration
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment